Insilico still feels the need for TEAD
Other new first-in-human trials involve CD74, where Gilead and Sutro tried and failed, and the emerging target MAT2A.
Other new first-in-human trials involve CD74, where Gilead and Sutro tried and failed, and the emerging target MAT2A.
The group was a first mover in stage III NSCLC, and now it hopes to repeat the trick in SCLC.
After two years Loqtorzi is on the US market at last, and Coherus looks to its Surface acquisition to play the combo game.